Pharmasaga Company Limited
Update：2025/12/24
Industries
Main Industry
Health Care
Main Product/Service
Currently, Pharmasaga has two Pdia4 inhibitors, PS-001 and PS-002, for type 2 diabetes (T2D) and type 1 diabetes (T1D), respectively. Their pre-clinical studies were completed in 2021.
US FDA approved the application of investigation drug (IND), PS-001. W
US FDA approved the application of investigation drug (IND), PS-001. W
Founded Year
2021
Unified Business No.
83379922
Status
Active
Number of Employees
0
Total Paid-in
Capital
535,365,800 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Pharmasaga is a spin-off of Academia Sinica and was founded in Jan 2021. Our core technology is a drug discovery platform composed of molecular docking, chemistry and biology for drug discovery, developed by Dr Wen-Chin Yang, Academia Sinica. With this pl
